Ngulube Peter
Department of Biological Sciences, Academy of Medical Sciences, Malawi University of Science and Technology, Thyolo, Malawi.
Infect Drug Resist. 2023 Apr 12;16:2147-2157. doi: 10.2147/IDR.S401247. eCollection 2023.
Malaria vaccines targeting the circumsporozoite protein (CSP) of the . parasite have been overall relatively promising. RTS, S is a pre-erythrocytic recombinant protein-based malaria vaccine that targets CSP. RTS, S effectiveness shows some limited success regardless of its 58% efficacy for severe disease. . circumsporozoite protein (Pfcsp) has stood to be the main candidate protein for most pre-erythrocytic stage vaccines. Studies on the structural and biophysical characteristics of antibodies specific to CSP (anti-CSP) are underway to achieve fine specificity with the CSP polymorphic regions. More recent studies have proposed the use of different kinds of monoclonal antibodies, the use of appropriate adjuvants, ideal vaccination dose and frequency, and improved targeting of particular epitopes for the robust production of functional antibodies and high complement-fixing activity as other potential methods for achieving long-lasting RTS, S. This review highlights recent findings regarding humoral immune responses to CSP elicited by RTS, S vaccine.
针对疟原虫环子孢子蛋白（CSP）的疟疾疫苗总体上相对有前景。RTS，S是一种基于重组蛋白的红细胞前期疟疾疫苗，靶向CSP。RTS，S的有效性显示出一定的有限成功，尽管其对重症疾病的疗效为58%。环子孢子蛋白（Pfcsp）一直是大多数红细胞前期疫苗的主要候选蛋白。目前正在进行针对CSP的特异性抗体（抗CSP）的结构和生物物理特性研究，以实现对CSP多态性区域的精细特异性。最近的研究提出使用不同种类的单克隆抗体、使用合适的佐剂、理想的疫苗接种剂量和频率，以及改进对特定表位的靶向，以强力产生功能性抗体和高补体固定活性，作为实现RTS，S持久效果的其他潜在方法。本综述重点介绍了关于RTS，S疫苗引发的对CSP的体液免疫反应的最新发现。
